Click on the highlighted text and dots or the menu to link directly to additional information about each of these topics.
Candidate | Indication | Mechanism of Action | Programme Status | Partner | |||
---|---|---|---|---|---|---|---|
Discovery Phase | Preclinical Development | Clinical Phase I | Clinical Phase II | ||||
IFN-β (SNG001) | COVID-19 | Virus Defence | ![]() |
![]() |
![]() |
![]() |
|
IFN-β (SNG001) | COPD | Virus Defence | ![]() |
![]() |
![]() |
![]() |
|
LOXL2 inhibitors | IPF, NASH, Kidney Fibrosis & Cardiac Fibrosis | Anti-fibrotic | ![]() |
![]() |
![]() |
![]() |
Pharmaxis |